SCHEMBL420607

SCHEMBL420607

C1=CN2C=Cc3ccccc3C2=CC1

nearest known ligand 0.31

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ABCB11 O95342 1/20 0.31
ALDH1A1 P00352 1/20 0.31
TP53 P04637 1/20 0.31
CYP1A2 P05177 1/20 0.31
CHRM2 P08172 1/20 0.31
CHRM4 P08173 1/20 0.31
HTR1A P08908 1/20 0.31
CHRM5 P08912 1/20 0.31
ADRA2A P08913 1/20 0.31
CYP2D6 P10635 1/20 0.31
CHRM1 P11229 1/20 0.31
DRD2 P14416 1/20 0.31
TSHR P16473 1/20 0.31
ADRA2B P18089 1/20 0.31
ADRA2C P18825 1/20 0.31
CHRM3 P20309 1/20 0.31
DRD1 P21728 1/20 0.31
TBXA2R P21731 1/20 0.31
SLC6A2 P23975 1/20 0.31
HRH2 P25021 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17540678 0.77
SCHEMBL8003373 0.72
SCHEMBL7387076 0.69 KDM4E (0.31) ALDH1A1HSD17B10MEN1LMNAMAPT
SCHEMBL10642347 0.68 ALDH1A1 (0.33) ABCB11ALDH1A1TP53CYP1A2CHRM2
SCHEMBL17284104 0.68
SCHEMBL10375396 0.67 PTAFR (0.34) ABCB11ALDH1A1TP53CYP1A2CHRM2
SCHEMBL20425270 0.66 KDM4E (0.32) ALDH1A1HSD17B10MEN1LMNAMAPT
SCHEMBL18955341 0.64 ABCB11 (0.31) ABCB11ALDH1A1TP53CYP1A2CHRM2
SCHEMBL11775709 0.64 ABCB11 (0.31) ABCB11ALDH1A1TP53CYP1A2CHRM2
SCHEMBL10839999 0.63 ABCB11 (0.30) ABCB11ALDH1A1TP53CYP1A2CHRM2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 145 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20150336951-A1 Process For The Preparation Of A DPP-IV Inhibitor HOFFMANN-LA ROCHE INC. 2015-11-26 US claimed
US-20150252039-A1 Process For The Preparation Of Pyrido[2,1-a] Isoquinoline Derivatives By Catalytic Asymmetric Hydrogenation Of An Enamine HOFFMANN-LA ROCHE INC. 2015-09-10 US claimed
US-20150126743-A1 Process For The Preparation Of Pyrido [2,1-A] Isoquinoline Derivatives Comprising Optical Resolution Of An Enamine HOFFMANN-LA ROCHE INC. 2015-05-07 US claimed
US-20150031888-A1 PROCESS FOR THE PREPARATION OF PYRIDO[2,1-a] ISOQUINOLINE DERIVATIVES BY CATALYTIC ASYMMETRIC HYDROGENATION OF AN ENAMINE F. HOFFMANN-LA ROCHE AG (CH) 2015-01-29 US claimed
US-20140350257-A1 Process for the Preparation of a DPP-IV Inhibitor F. HOFFMANN-LA ROCHE AG (CH) 2014-11-27 US claimed
US-20140187785-A1 PROCESS FOR THE PREPARATION OF PYRIDO[2,1-a] ISOQUINOLINE DERIVATIVES BY CATALYTIC ASYMMETRIC HYDROGENATION OF AN ENAMINE HOFFMANN-LA ROCHE INC. (US) 2014-07-03 US claimed
US-20140046066-A1 PROCESS FOR THE PREPARATION OF DPP-IV INHIBITOR HOFFMANN-LA ROCHE INC. (US) 2014-02-13 US claimed
US-20130338366-A1 PROCESS FOR THE PREPARATION OF PYRIDO [2,1-A] ISOQUINOLINE DERIVATIVES COMPRISING OPTICAL RESOLUTION OF AN ENAMINE HOFFMANN LA ROCHE (US) 2013-12-19 US claimed
US-20130109859-A1 PROCESS FOR THE PREPARATION OF PYRIDO[2,1-a] ISOQUINOLINE DERIVATIVES BY CATALYTIC ASYMMETRIC HYDROGENATION OF AN ENAMINE HOFFMANN-LA ROCHE INC. (US) 2013-05-02 US claimed
US-8420818-B2 Process for the preparation of pyrido[2,1-a] isoquinoline derivatives HOFFMANN-LA ROCHE INC. (US) 2013-04-16 US claimed
WO-2009027276-A1 PROCESS FOR THE PREPARATION OF PYRIDO [2, 1-A] ISOQUINOLINE DERIVATIVES AND POLYMORPHIC FROMS THEREOF F. HOFFMANN-LA ROCHE AG (CH) 2009-03-05 WO claimed
US-20080108816-A1 PROCESS FOR THE PREPARATION OF (S)-4-FLUOROMETHYL-DIHYDRO-FURAN-2-ONE F. HOFFMANN-LA ROCHE AG (CH) 2008-05-08 US claimed
US-20080076925-A1 PROCESS FOR THE PREPARATION OF PYRIDO [ 2-1-A] ISOQUINOLINE DERIVATIVES BY CATALYTIC ASYMMETRIC HYDROGENATION OF AN ENAMINE F. HOFFMANN-LA ROCHE AG (CH) 2008-03-27 US claimed
WO-2008031749-A1 PROCESS FOR THE PREPARATION OF PYRIDO[2,1-A]ISOQUINOLINE DERIVATIVES COMPRISING OPTICAL RESOLUTION OF AN ENAMINE F. HOFFMANN-LA ROCHE AG (CH) 2008-03-20 WO claimed
US-20080071087-A1 PROCESS FOR THE PREPARATION OF PYRIDO [2,1-a] ISOQUINOLINE DERIVATIVES COMPRISING OPTICAL RESOLUTION OF AN ENAMINE HOFFMAN-LA ROCHE INC. 2008-03-20 US claimed
WO-2008031750-A2 PROCESS FOR THE PREPARATION OF PYRIDO[2,1-A]ISOQUINOLINE DERIVATIVES BY CATALYTIC ASYMMETRIC HYDROGENATION OF AN ENAMINE F. HOFFMANN-LA ROCHE AG (CH) 2008-03-20 WO claimed
WO-2007041294-A2 METHODS FOR SENSITIZING CANCER CELLS TO INHIBITORS THE TRUSTEES OF BOSTON UNIVERSITY (US) 2007-04-12 WO claimed
US-20060270853-A1 Process for the preparation of (S)-4-fluoromethyl-dihydro-furan-2-one useful in the preparation of the DPP-IV inhibitor (S)-1 ((2S,3S,11bS)-2-amino-9,10-dimethoxy-1,3,4,6,7, 11b-hexahydro-2h-pyrido[2,1-a] isoquinolin-3-yl)-4-fluoromethyl-pyrrolidin-2-one HOFFMANN-LA ROCHE INC. 2006-11-30 US claimed
EP-0120637-B1 BENZOQUINOLIZINES JOHN WYETH & BROTHER LIMITED (GB) 1988-01-20 EP claimed
EP-0079123-B1 BENZOQUINOLIZINES JOHN WYETH & BROTHER LIMITED (GB) 1985-09-04 EP claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080076925-A1 PROCESS FOR THE PREPARATION OF PYRIDO [ 2-1-A] ISOQUINOLINE DERIVATIVES BY CATALYTIC ASYMMETRIC HYDROGENATION OF AN ENAMINE PNISR, SFPQ, PLPBP ABCB11 4754/4885ALDH1A1 3416/4885TP53 2016/4885
US-20130109859-A1 PROCESS FOR THE PREPARATION OF PYRIDO[2,1-a] ISOQUINOLINE DERIVATIVES BY CATALYTIC ASYMMETRIC HYDROGENATION OF AN ENAMINE IDO2, IDO1, H1-2 ABCB11 4540/4885ALDH1A1 3110/4885TP53 1857/4885
US-20150031888-A1 PROCESS FOR THE PREPARATION OF PYRIDO[2,1-a] ISOQUINOLINE DERIVATIVES BY CATALYTIC ASYMMETRIC HYDROGENATION OF AN ENAMINE IDO2, IDO1, H1-2 ABCB11 4540/4885ALDH1A1 3110/4885TP53 1857/4885
US-20140046066-A1 PROCESS FOR THE PREPARATION OF DPP-IV INHIBITOR DPP4, DPP3, DPP7 ABCB11 1520/4885ALDH1A1 94/4885TP53 4565/4885
US-20140350257-A1 Process for the Preparation of a DPP-IV Inhibitor DPP4, DPP3, DPP7 ABCB11 1229/4885ALDH1A1 136/4885TP53 4504/4885
US-20080108816-A1 PROCESS FOR THE PREPARATION OF (S)-4-FLUOROMETHYL-DIHYDRO-FURAN-2-ONE DPP4, DPP7, DPP3 ABCB11 1486/4885ALDH1A1 98/4885TP53 4530/4885
US-20130338366-A1 PROCESS FOR THE PREPARATION OF PYRIDO [2,1-A] ISOQUINOLINE DERIVATIVES COMPRISING OPTICAL RESOLUTION OF AN ENAMINE PNPO, ENO1, CHRM1 ABCB11 2876/4885ALDH1A1 1362/4885TP53 4381/4885
US-20150336951-A1 Process For The Preparation Of A DPP-IV Inhibitor DPP4, DPP3, DPP7 ABCB11 1229/4885ALDH1A1 136/4885TP53 4504/4885
US-20060270853-A1 Process for the preparation of (S)-4-fluoromethyl-dihydro-furan-2-one useful in the preparation of the DPP-IV inhibitor (S)-1 ((2S,3S,11bS)-2-amino-9,10-dimethoxy-1,3,4,6,7, 11b-hexahydro-2h-pyrido[2,1-a] isoquinolin-3-yl)-4-fluoromethyl-pyrrolidin-2-one DPP4, DPP7, DPP3 ABCB11 2119/4885ALDH1A1 70/4885TP53 4571/4885
US-20150252039-A1 Process For The Preparation Of Pyrido[2,1-a] Isoquinoline Derivatives By Catalytic Asymmetric Hydrogenation Of An Enamine IDO2, IDO1, H1-2 ABCB11 4540/4885ALDH1A1 3110/4885TP53 1857/4885
US-20150126743-A1 Process For The Preparation Of Pyrido [2,1-A] Isoquinoline Derivatives Comprising Optical Resolution Of An Enamine PNPO, ENO1, CHRM1 ABCB11 2876/4885ALDH1A1 1362/4885TP53 4381/4885
US-20140187785-A1 PROCESS FOR THE PREPARATION OF PYRIDO[2,1-a] ISOQUINOLINE DERIVATIVES BY CATALYTIC ASYMMETRIC HYDROGENATION OF AN ENAMINE IDO2, IDO1, H1-2 ABCB11 4540/4885ALDH1A1 3110/4885TP53 1857/4885
US-20080071087-A1 PROCESS FOR THE PREPARATION OF PYRIDO [2,1-a] ISOQUINOLINE DERIVATIVES COMPRISING OPTICAL RESOLUTION OF AN ENAMINE PNPO, ENO1, CHRM1 ABCB11 2876/4885ALDH1A1 1362/4885TP53 4381/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.